Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 20/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7685880 | 0.99 | LSS (0.98) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL4437311 | 0.96 | LSS (1.00) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL3189902 | 0.96 | LSS (1.00) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL29455114 | 0.96 | LSS (1.00) | LSSMEN1KMT2A | |
| SCHEMBL8760830 | 0.94 | LSS (0.89) | LSSMEN1KMT2A | |
| SCHEMBL21114026 | 0.91 | LSS (0.84) | LSSMEN1KMT2A | |
| Fumaric Acid SCHEMBL12477423 | 0.91 | LSS (0.90) | LSSMEN1KMT2A | |
| SCHEMBL7684557 | 0.89 | LSS (0.80) | LSSMEN1KMT2A | |
| SCHEMBL7679409 | 0.89 | LSS (1.00) | LSSMEN1KMT2A | |
| SCHEMBL7686324 | 0.88 | LSS (0.80) | LSSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000076316-A1 | METHODS RELATED TO METABOLISM OF PARASITES AND MYCOBACTERIA | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-12-21 | — | — | WO | claimed |
| EP-0636367-B1 | Use of phenylalkylamines for producing cholesterol lowering agents | HOFFMANN LA ROCHE (CH) | 2000-03-29 | — | — | EP | claimed |
| US-5574071-A | ADMINISTERING PHENYLALKYLAMINO KETONES | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | claimed |
| US-12428662-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2025-09-30 | — | — | US | disclosed |
| US-12403104-B2 | Compounds and methods of promoting myelination | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-12338476-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2025-06-24 | — | — | US | disclosed |
| US-12286661-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2025-04-29 | — | — | US | disclosed |
| CN-119709929-A | Method for preparing high intensity sweetener | 弗门尼舍公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250034091-A1 | Small molecule inhibitors of lanosterol synthase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-30 | — | — | US | disclosed |
| CN-111108213-B | Method for preparing high intensity sweetener | 弗门尼舍公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2000076316-A1 | METHODS RELATED TO METABOLISM OF PARASITES AND MYCOBACTERIA | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0636367-B1 | Use of phenylalkylamines for producing cholesterol lowering agents | HOFFMANN LA ROCHE (CH) | 2000-03-29 | — | — | EP | disclosed |
| US-6034275-A | FUGICIDES; ATICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0778264-A1 | Tertiary amines having antimycotic and cholesterol lowering activity | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-11 | — | — | EP | disclosed |
| EP-0778271-A2 | Aminoalkyl-substituted benzo-heterocyclic compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-11 | — | — | EP | disclosed |
| US-5637771-A | Compound useful for lowering cholesterol | HOFFMANN-LA ROCHE INC. (US) | 1997-06-10 | — | — | US | disclosed |
| US-5574071-A | ADMINISTERING PHENYLALKYLAMINO KETONES | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5495048-A | ANTICHOLESTEROL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0636367-A1 | Use of phenylalkylamines for producing cholesterol lowering agents | F. HOFFMANN-LA ROCHE AG (CH) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034091-A1 | Small molecule inhibitors of lanosterol synthase | LSS, CYP51A1, CYP27A1 | LSS 1/4885MEN1 2088/4885KMT2A 4011/4885 |
| US-12403104-B2 | Compounds and methods of promoting myelination | GMFG, MAG, SGMS1 | LSS 78/4885MEN1 3605/4885KMT2A 2028/4885 |
| US-12428662-B2 | Methods for making high intensity sweeteners | OXER1, MAN1B1, GMDS | LSS 17/4885MEN1 2587/4885KMT2A 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.